Revolution Medicines (RVMD) revenue
Revolution Medicines (RVMD) reported revenue of $11.58M in fiscal 2023 (the year ended December 31, 2023). That is 67.3% lower than the $35.38M of fiscal 2022. Figures as of 18 Nov 2026, 09:50 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2023
- $11.58M
- Change on fiscal 2022
- −67.3%
- Growth, 5 years
- −10.5% a year
- Highest on record
- $50.04Mfiscal 2019
- Lowest on record
- $11.58Mfiscal 2023
- Fiscal years on record
- 62018–2023
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Revolution Medicines revenue, in more detail
Over the five fiscal years to 2023 revenue shrank at a compound 10.5% a year. Across the 6 fiscal years on record (2018–2023), the highest was $50.04M in fiscal 2019 and the lowest $11.58M in fiscal 2023.
Revenue by fiscal year
Revolution Medicines revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2023 | $11.58M | 67.3% down | |
| 2022 | $35.38M | 20.4% up | |
| 2021 | $29.39M | 31.6% down | |
| 2020 | $42.98M | 14.1% down | |
| 2019 | $50.04M | 148.2% up | |
| 2018 | $20.17M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Revenue at health care companies of similar size
| Company | Revenue | Fiscal year |
|---|---|---|
| BeOne Medicines ONC | $5.34B | 2025 |
| Waters WAT | $3.17B | 2025 |
| Natera NTRA | $2.31B | 2025 |
| IQVIA Holdings IQV | $16.31B | 2025 |
| Revolution Medicines RVMD | $11.58M | 2023 |
| Royalty Pharma RPRX | $2.38B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Revolution Medicines, figure by figure
- Revolution Medicines market cap
- Revolution Medicines earnings
- Revolution Medicines earnings per share (EPS)
- Revolution Medicines P/E ratio
- Revolution Medicines P/S ratio
- Revolution Medicines P/B ratio
- Revolution Medicines free cash flow
- Revolution Medicines operating margin
- Revolution Medicines dividend
- Revolution Medicines shares outstanding
- Revolution Medicines total debt
- Revolution Medicines cash on hand
- Revolution Medicines total assets
- Revolution Medicines return on equity (ROE)
- Revolution Medicines return on invested capital (ROIC)
Revolution Medicines (RVMD) overview: price, valuation and scorecardAll health care companies by market value
Revolution Medicines revenue: questions and answers
What is Revolution Medicines's revenue?
Revolution Medicines (RVMD) reported revenue of $11.58M in fiscal 2023 (the year ended December 31, 2023). That is 67.3% lower than the $35.38M of fiscal 2022.
What is the growth rate of Revolution Medicines's revenue?
Over the five fiscal years to 2023 revenue shrank at a compound 10.5% a year.
What are the highest and lowest revenue figures on record for Revolution Medicines?
Across the 6 fiscal years on record (2018–2023), the highest was $50.04M in fiscal 2019 and the lowest $11.58M in fiscal 2023.
How is Revolution Medicines's revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Revolution Medicines it is on record here for 6 fiscal years, 2018 to 2023.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Revolution Medicines (RVMD) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/RVMD/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.